Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to ...

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...

It has been a volatile year for the biotech.

A Delaware federal judge on Monday rejected requests from Pfizer (PFE), BioNTech (BNTX), and Moderna (MRNA) to dismiss lawsuits filed against them by Bayer's (BAYZF)(BAYRY) Monsanto unit regarding the ...

Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements.

Pfizer (NYSE:PFE) and its German partner BioNTech (BNTX) disclosed Phase 2/3 data on Saturday to indicate that the companies’ Omicron-adapted vaccine candidates generated a stronger immune response ...